New drug combo targets stubborn leukemia cells in rare ALL subtype
NCT ID NCT07301138
First seen Jan 04, 2026 · Last updated May 16, 2026 · Updated 17 times
Summary
This study tests a new drug called BEBT-908 combined with chemotherapy in adults with a rare form of acute lymphoblastic leukemia (ALL) that has a specific gene change (MEF2D). Participants are in remission but still have tiny amounts of cancer cells detectable (MRD positive). The goal is to see if the combo can clear those leftover cells and improve long-term outcomes. About 23 people will take part across multiple hospitals.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Ruijin Hospital, Shanghai Jiaotong University School of Medicine
Shanghai, Shanghai Municipality, 200025, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.